Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Monday 22 January 2024

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Announces Closing of Uncle Bud's Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales; @ir_pressurebio

  

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Announces Closing of Uncle Bud's Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales; @ir_pressurebio

 

Merged Companies Will Introduce Revolutionary New Product Capabilities Across Multiple Major Market Sectors, Expecting 2024 Revenues of Over $10 Million, Then Accelerating in Future Years

 



 

SOUTH EASTON, Mass. - January 22, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced the closing of its acquisition of natural health and wellness leader Uncle Bud's ("UB") in an all-stock transaction. Incorporating UB's 70+ already popular products, 865K member on-line community, existing sales channels online and with leading large retailers, enviable celebrity spokesperson relationships, and invaluable experience building successful consumer products businesses, PBIO will leverage and integrate the Company's revolutionary UltraShear™ technology (UltraShear™ or UST™) platform for further improved nanoemulsified products that deliver industry-leading speed of action, effective dosing payload delivery, and long-term stability. With these unique product improvement and differentiation capabilities, PBIO intends to redefine the basis of competition in multiple major market sectors, and to become a leading provider of topicals and other consumer products.

 

Read this news, featuring PBIO in full at https://www.investorideas.com/news/2024/cannabis/01221PBIO-Uncle-Bud-Acquisition-UltraShear-Nanoemulsions.asp

 


Toni Braxton

Multi-award-winning singer, songwriter, actress, and long-term Uncle Bud's advocate and spokesperson.

Transaction Terms

Under the terms of the transaction, PBIO acquired all assets and assumed selected liabilities of UB. In addition, the parties agreed to an earnout for additional shares of PBIO Common Stock based on the achievement of revenue and pre-tax income results in 2024. Upon closing, all employees of UB became employees of PBIO and UB became the Consumer Products Business Unit of PBIO. More definitive transaction terms will be included in the Company's upcoming SEC filings.

 

Significance of the Transaction

  • The transaction is expected to be immediately accretive and a major accelerator to PBIO's top line revenue growth.
  • The combined companies will be ideally positioned to attract new growth investment, rapidly strengthen their balance sheet, accelerate PBIO's path to profitability in 2024, and catalyze our drive to uplist to NASDAQ/NYSE.
  • The co-founders/senior management of UB are experts in branding, celebrity spokesperson management, and online and retail multimedia marketing.
  • UB will rapidly incorporate PBIO's best-in-class Nano-CBD into their already highly renowned and successful CBD products, for new market breakaway potential!
  • Senior management of UB and PBIO are already planning a dozen new products that they believe could be formulated and released in 2024, just using PBIO's existing UltraShear processed Nano CBD.
  • UB markets and sells many products in the health & wellness area that are unrelated to Hemp and CBD.
  • UB has an ongoing partnership with multi-Grammy award-winning Toni Braxton as a highly successful marketing ambassador - and Toni has announced that she is excited to continue as a PBIO/UB spokesperson going forward.
  • UB has been featured, as well as their hemp and CBD products, in an extensive variety of high profile news outlets and magazines online over the past several years: https://www.unclebudshemp.com/press/.

 

Expected Financial Impact

PBIO's President and CEO, Richard T. Schumacher, summarized: "This transaction combines the existing momentum and ready market execution power of Uncle Bud's with the pivotal scientific and product breakthrough of the UltraShear nanoemulsions processing platform for record-setting product performance and long-term stability. In 2024 alone, we are forecasting a 5-fold leap forward in PBIO revenues to over $10 million, but this is only a steppingstone towards revolutionary impact and sales growth that we expect to achieve across the nutraceuticals, cosmeceuticals, skincare, food/beverage, agrochemical, and other major markets in the following years."

 

Jeffrey N. Peterson, PBIO's Chairman, added: "Our Board and leadership team have carefully sought out this strategic combination of Uncle Bud's marketing skill and power to combine with PBIO's world class scientific innovation team. Specifically, this positions PBIO with a fast forward integration capability that will allow us to selectively set the timing and drive the pace of revolutionary change across multiple major markets. This rapid growth engine provides a central platform to leverage new growth capital, restructure and strengthen our balance sheet, and complete our drive to uplist to a national stock exchange in 2024."

 

About Uncle Bud's

Officially launched in September 2018 with one hero product, Uncle Bud's has experienced unequivocal growth. As a leader in the Hemp and CBD space, Uncle Bud's takes pride in being Made in America, GMO Free, Cruelty Free and Leaping Bunny Certiļ¬ed. The full range includes Hemp & CBD products for pain relief, skincare, personal care, and even pet care - all retailing under $45. To learn more about Uncle Bud's visit unclebudshemp.com as well as their associated Instagram: @UncleBuds_Hemp; Facebook: @UncleBuds_Hemp and Twitter: @UncleBuds_Hemp.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:
http://www.pressurebiosciences.com www.unclebudshemp.com


Please visit us on Facebook, LinkedIn, and Twitter.

 

Press Contacts

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 


 Investorideas.com potcasts - Listen to Investor Ideas Potcasts Cannabis News and Stocks on the Move

 

Check out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks plus the new psychedelic stock directory

 

 

Follow Pot stocks news - Get News Alerts on Marijuana Stocks

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Tuesday 28 November 2023

Hemp Stock News: Hempacco (NASDAQ: HPCO) Launches THCA Vapes with Snoop Dogg at the MJBizCon in Las Vegas, Booth #7512

Hemp Stock News: Hempacco (NASDAQ: HPCO) Launches THCA Vapes with Snoop Dogg at the MJBizCon in Las Vegas, Booth #7512: Hemp Stock News: Hempacco (NASDAQ: HPCO) Launches THCA Vapes with Snoop Dogg at the MJBizCon in Las Vegas, Booth #7512

Investor Ideas Potcasts: Interview with Kaya Holdings (OTCQB: $KAYS) on the Sacred Mushroom Center - Pioneers with Psilocybin and Advocates for Mental Health; @KayaHoldings

 





 

Investor Ideas Potcasts: Interview with Kaya Holdings (OTCQB: $KAYS) on the Sacred Mushroom Center - Pioneers with Psilocybin and Advocates for Mental Health; @KayaHoldings

 

November 28, 2023 (Investorideas.com Newswire), Investorideas.com, a global news source covering leading sectors including marijuana and psychedelic stocks releases a special edition of  the top rated Investor Ideas potcast (Cannabis Podcast).

 

In today’s episode, Investor Idea’s host Cali Van Zant speaks with CEO Craig Frank and Senior Consultant Dave Jones of Kaya Holdings Inc (OTCQB: KAYS).

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2023/112223-Cannabis.mp3

 

Read this in full at https://www.investorideas.com/news/2023/cannabis-potcasts/11281Interview-Kaya-Holdings.asp

 

Kaya Holdings, Inc. is a mind care company focusing on wellness and mental health through their operations in medical and recreational cannabis, CBD products and psychedelic treatment clinics.

 

Kaya has the historical distinction of being the first US publicly traded company to hold and operate cannabis licenses in “touch the plant” categories from when it commenced cannabis operations in Portland, Oregon in 2014.

 

In today’s podcast, management discusses the new opportunities in the medical psychedelic market and how Kaya Holdings is leading the way as an innovator and pioneer in the sector. They also talk about their recent milestone of opening one of the first state licensed Psilocybin Treatment Centers in the United States, in Portland, Oregon. 

 

Host Cali Van Zant says, “What makes this podcast special is to hear management go deep and share their personal experiences and show that they care about community. We discuss mental health and how it personally affects us all. It is a rare opportunity to get such personal insight from a management team and the opportunity to find a public company with heart. I hope you all enjoy listening and share this interview.”

 

To learn more about Kaya holdings you can visit their website at (www.kayaholdings.com) or reach out to the team at info@kayaholdings.com

 

Today’s podcast overview

 

When talking about the new Sacred Mushroom space, CEO Craig Frank notes, It is very important to us that the facility be in a central location because we think community is a big part of the healing process. We were very lucky to find the perfect location.”

 

“The space is the entire top floor of the Falcon Building in downtown Portland. At about 11,000 square feet, we have the area we need to offer both private and group experiences, as well as creativity centers, sensory rooms, reflection areas, and the room to roam and explore. We are equipped with a full kitchen and will be able to provide food consistent with Oregon regulation….

 

I think there are four primary differences between us and what we have seen so far. I would say the first difference is the space itself. A huge contributing factor in the quality of an experience is the setting and ours is extraordinary. Another difference would be the extent to which we aim to cater the journey to individual preference, with sound, sight, and scent options and the activity options presented. Third, I would say the community we seek to create. While we will cater to out-of-state visitors, our emphasis is on serving the needs of the Greater Portland area. Finally, I would say our pricing model is different. We are aiming to enable sustained treatment to those who seek it, so we have some less expensive microdosing options.”

 

When talking about other companies in the psilocybin space, he went on to say, “The work of companies like ATAI Life Sciences (NASDAQ: ATAI) and Compass Pathways (NASDAQ:CMPS) is fascinating and we are excited to see what their research can teach all of us about the medicinal possibilities of psilocybin.

 

CMPS is developing its own synthetic versions of that they then plan to administer in their own treatment facilities. Our model calls for the use of natural psilocybin and psilocin in our own facilities.  We believe our model is more immediate and allows us to avoid the long, laborious, and very costly FDA process. We expect to begin offering treatments immediately upon licensing of our facility…”

 

When talking about the personal reasons for building a treatment center and working in the Psilocybin space, Frank says, “I would say that it is hard to find an American family that does not have someone with a mental disorder effecting their personal story whether it be a sibling, a parent, a child, or a friend. There is something in the way we live that causes profound pain and disorder in some people and our involvement is in some ways motivated to bring this relief; to those we love and those other people love.”

 

About Kaya Holdings, Inc. (www.kayaholdings.com )

Kaya Holdings, Inc is a "mind care" company with operations in medical/recreational cannabis and pending operations in the emerging psilocybin sector. KAYS is a fully reporting, US-based publicly traded company, listed for trading on the over-the-counter market under the symbol KAYS.

 

In 2014, KAYS became the first US public company to own and operate a medical cannabis dispensary (in Portland, Oregon). The Company still operates the original Kaya Shack™ cannabis dispensary while seeking to shift our cannabis operations to serve the European Union. KAYS has interests in three medical cannabis licenses (2 in Greece, 1 in Israel) to advance this effort.

 

Resuming its role as innovator and trend setter, the Company is again breaking ground in the United States with the planned introduction of psilocybin treatment centers through our majority owned subsidiary, Fifth Dimension Therapeutics, Inc. ("FDT").

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water.

 

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: KAYS is a paid for monthly featured stock on Investorideas.com. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.



Investorideas.com potcasts
 - Listen Daily to Investor Ideas Potcasts #Cannabis News and Stocks on the Move

 

Check out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks plus the new psychedelic stock directory!

Follow Pot stocks news - Get News Alerts on Marijuana Stocks

 

Drug Enforcement Agency (DEA) Reschedules Cannabis from Schedule I to Schedule III

Drug Enforcement Agency (DEA) Reschedules Cannabis from Schedule I to Schedule III : Drug Enforcement Agency (DEA) Reschedules Cannabis from...